Literature DB >> 17110278

Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis.

Nigel J Fullwood, Yoshihito Hayashi, David Allsop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17110278     DOI： 10.1016/S1474-4422(06)70611-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  6 in total

1.  Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Authors:  K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

Review 2.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

3.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.

Authors:  Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.

Authors:  Weiming Xia; Ting Yang; Ganesh Shankar; Imelda M Smith; Yong Shen; Dominic M Walsh; Dennis J Selkoe
Journal:  Arch Neurol       Date:  2009-02

5.  Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.

Authors:  Katarzyna A Gustaw-Rothenberg; Sandra L Siedlak; David J Bonda; Alan Lerner; Massimo Tabaton; George Perry; Mark A Smith
Journal:  Exp Gerontol       Date:  2009-10-09       Impact factor: 4.032

6.  Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.

Authors:  Vincent Damotte; Sven J van der Lee; Vincent Chouraki; Benjamin Grenier-Boley; Jeannette Simino; Hieab Adams; Giuseppe Tosto; Charles White; Natalie Terzikhan; Carlos Cruchaga; Maria J Knol; Shuo Li; Susanna Schraen; Megan L Grove; Claudia Satizabal; Najaf Amin; Claudine Berr; Steven Younkin; Rebecca F Gottesman; Luc Buée; Alexa Beiser; David S Knopman; Andre Uitterlinden; Charles DeCarli; Jan Bressler; Anita DeStefano; Jean-François Dartigues; Qiong Yang; Eric Boerwinkle; Christophe Tzourio; Myriam Fornage; M Arfan Ikram; Philippe Amouyel; Phil de Jager; Christiane Reitz; Thomas H Mosley; Jean-Charles Lambert; Sudha Seshadri; Cornelia M van Duijn
Journal:  Alzheimers Dement       Date:  2021-05-18       Impact factor: 21.566
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.